Tavexia Lifecare Limited has announced key corporate decisions following a Board of Directors meeting on September 7, 2026. The company accepted the resignation of its statutory auditors, M/s SSRV & Associates, and appointed M/s DEVAM & Associates LLP as their replacement, pending member approval. Additionally, Tavexia Lifecare is exploring the acquisition of up to 60% equity share capital in Meyonex Pharmaceuticals Limited, authorizing directors to conduct preliminary evaluations and negotiations.
Tavexia Lifecare Board Meeting Highlights
Tavexia Lifecare Limited held a significant Board of Directors meeting on September 7, 2026. The meeting addressed critical changes in the company’s auditing structure and strategic growth initiatives. Key decisions included the resignation of the current statutory auditors and the initiation of a potential acquisition.
Auditor Change
The Board acknowledged and accepted the resignation of M/s SSRV & Associates, Chartered Accountants, from their role as the company’s Statutory Auditors, effective September 7, 2026. In their place, the Board approved the appointment of M/s DEVAM & Associates LLP, Chartered Accountants, as the new Statutory Auditors. This appointment is subject to the approval of the company’s members at the upcoming General Meeting and is for a term of five consecutive years, commencing from the financial year 2026-27.
Exploration of Acquisition
A major strategic move discussed was the proposal for the acquisition of up to 60% equity share capital in Meyonex Pharmaceuticals Limited, an unlisted public company. The Board authorized directors Mr. Chirag Deepak Dedhia and Mr. Sachin Bhanubhai Manseta to jointly or severally undertake preliminary evaluation, due diligence, valuation, and negotiations. This includes discussing commercial, financial, and legal terms, obtaining necessary information, and appointing professional advisors for the process. Meyonex Pharmaceuticals Limited is in the pharmaceutical industry.
Other Key Decisions
The Board also approved the re-appointment of Mrs. Khushboo Vasudev as an Independent Director for a second term of five years, pending shareholder approval. Furthermore, approvals were granted for the proposed limit for Material Related Party Transactions, the adoption of the Board Report and Corporate Governance Report for the financial year ended March 31, 2026, and the fixation of the date for the 46th Annual General Meeting (AGM) and related book closure period from September 24, 2026, to September 30, 2026. Mr. Brajesh Gupta was appointed as Scrutinizer for the e-voting process for the AGM.
Source: BSE
